<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40341">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106923</url>
  </required_header>
  <id_info>
    <org_study_id>1276.14</org_study_id>
    <nct_id>NCT02106923</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets</brief_title>
  <official_title>Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate the relative bioavailability of 2 newly
      developed fixed dose combinations (FDC) tablets containing empagliflozin &amp; metformin XR and
      the single tablets of empagliflozin and metformin XR when administered singularly
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point), for empagliflozin and metformin</measure>
    <time_frame>up to 72 hours after administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma, for empagliflozin and metformin</measure>
    <time_frame>up to 72 hours after administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity), for empagliflozin and metformin</measure>
    <time_frame>up to 72 hours after administration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High dose, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose, fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose, fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tablet Empagliflozin/2 tablets Metformin XR</intervention_name>
    <description>Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets</description>
    <arm_group_label>High dose, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Empagliflozin/1000 mg Metformin XR</intervention_name>
    <description>Experimental: high dose Empagliflozin/Metformin XR, FDC tablet</description>
    <arm_group_label>High dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tablet 10 mg Empagliflozin/3 tablets Metformin XR</intervention_name>
    <description>Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets</description>
    <arm_group_label>Low dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 tablets 5 mg Empagliflozin/750 Metformin XR</intervention_name>
    <description>Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets</description>
    <arm_group_label>Low dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 tablet Empagliflozin/2 tablets Metformin XR</intervention_name>
    <description>Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets</description>
    <arm_group_label>High dose, fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Empagliflozin/1000 mg Metformin XR</intervention_name>
    <description>Experimental: high dose Empagliflozin/Metformin XR, FDC tablet</description>
    <arm_group_label>High dose, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males or females

          2. Age 18-50 years (incl.)

          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)

          4. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

        Any deviation from healthy condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1276.14.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
